Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods

15 Feb 2016

Abstract excerpt

Myeloid cell leukemia-1 (Mcl-1) is a member of the Bcl-2 family of proteins responsible for the regulation of programmed cell death. Amplification of Mcl-1 is a common genetic aberration in human cancer whose overexpression contributes to the evasion of apoptosis and is one of the major resistance mechanisms for many chemotherapies. Mcl-1 mediates its effects primarily through interactions with pro-apoptotic BH3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Chronic Myeloid Leukemia Treatments
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26878343
DOI: 10.1021/acs.jmedchem.5b01660

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based MethodsPMID 26878343Read ↗

Discovery of Potent MyeloidCell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods andStructure-Based DesignSemantic proximity Read ↗

Mcl-1 inhibitors: a patent reviewSemantic proximity Read ↗

Toward Targeting Antiapoptotic MCL-1 for Cancer TherapySemantic proximity Read ↗

Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1Semantic proximity Read ↗

Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)Semantic proximity Read ↗

Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells.Semantic proximity Read ↗

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSemantic proximity Read ↗

Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in CellsSemantic proximity Read ↗

Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.Semantic proximity Read ↗

MCL-1 inhibitors – where are we now (2019)?Semantic proximity Read ↗

A luciferase-based assay identifies niclosamide derivatives antagonizing Mcl-1 through post-translational down-regulationSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.